Effects of additional blood pressure and lipid measurements on the prediction of cardiovascular risk

European Journal of Preventive Cardiology

Volumn 19, Issue 6, 2012, Pages 1474-1485

  Bell, Katy ^a   Hayen, Andrew ^a   McGeechan, Kevin ^a   Neal, Bruce ^a   Irwig, Les ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Blood pressure; cardiovascular diseases; cholesterol; reproducibility of results; risk assessment; risk factors

Indexed keywords

ANTIHYPERTENSIVE AGENT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; FEMALE; FRAMINGHAM RISK SCORE; HUMAN; HYPERTENSION; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; SMOKING; SYSTOLIC BLOOD PRESSURE;

ADULT; AGE FACTORS; AGED; BIOLOGICAL MARKERS; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; CARDIOVASCULAR DISEASES; CHOLESTEROL; CHOLESTEROL, HDL; DECISION SUPPORT TECHNIQUES; FEMALE; HUMANS; MALE; MASSACHUSETTS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS;

EID: 84873913939     PISSN: 20474873     EISSN: None     Source Type: Journal    
DOI: 10.1177/1741826711424494     Document Type: Article

References (32)

1. National Vascular Disease Prevention Alliance. Guidelines for the assessment of absolute cardiovascular disease risk. 2009.
2. New Zealand Guideline Group. The assessment and management of cardiovascular risk. Available at: www.nzgg.org.nz [2003, consulted March 2009].
3. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur J Cardiovasc Prev Rehab. 2007 ; 14 (Supplement 2). E1 - E40
4. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart. 2005 ; 91 (Suppl V). v1 - v52
5. D'Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care The Framingham Heart Study. Circulation. 2008 ; 117 (6). 743-753
6. Jackson R, Lawes C, Bennet D, Milne R, Roders A. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. Lancet. 2005 ; 365 (9457). 434-441
7. Bell KJL, Irwig L, Craig JC, Macaskill P. Use of randomized trials to decide when to monitor response to new treatment. BMJ. 2008 ; 336 (7640). 361-365
8. Bell KJL, Hayen A, Macaskill P, Craig JC, Neal BC, Irwig L. Mixed models showed no need for initial response monitoring after starting anti-hypertensive therapy. J Clin Epidemiol. 2009 ; 62 (6). 650-659
9. Glasziou PP, Irwig L, Heritier S, Simes J, Tonkin A. The LIPID Study Investigators.. Monitoring cholesterol levels: measurement error or true change?. Ann Intern Med. 2008 ; 148 (9). 656-661
10. Reynolds TM, Twomey P, Wierzbicki AS. Accuracy of cardiovascular risk estimation for primary prevention in patients without diabetes. J Cardiovasc Risk. 2002 ; 9 (4). 183-190
11. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, May M, Brindle P. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ. 2007 ; 335 (7611). 136-136
12. Woodward M, Brindle P, Tunstall-Pedoe H. Sign Group on Risk Estimation. Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC). Heart. 2007 ; 93 (2). 172-176
13. MacMahon S, Peto R, Collins R, Godwin J, Cutler J, Sorlie P, et al. Blood pressure, stroke, and coronary heart disease: Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990 ; 335 (8692). 765-774
14. Vasan RS, Massaro JM, Wilson PWF, Seshadri S, Wolf PA, Levy D, et al. Antecedent blood pressure and risk of cardiovascular disease.The Framingham Heart Study. Circulation. 2002 ; 105 (1). 48-53
15. Rothwell PM. Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension. Lancet. 2010 ; 375 (9718). 938-948
16. Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, Dahlöf B, et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet. 2010 ; 375 (9718). 895-905
17. Cupples LA, D'Agostino RB Framingham Heart Study: 30 year follow-up. Kannel WB Wolf PA Garrison RJ, ed. Bethesda: US Department of Health and Human Services ; 1987 :
18. McGeechan K, Macaskill P, Irwig L, Liew G, Wong TY. Assessing new biomarkers and predictive models for use in clinical practice. Arch Intern Med. 2008 ; 168 (21). 2304-2310
19. McGeechan K, Liew G, Macaskill P, Irwig L, Klein R, Klein BEK, et al. Prediction of incident stroke events based on retinal vessel caliber: a systematic review and individual-participant meta-analysis. Am J Epidemiol. 2009 ; 170 (11). 1323-1332
20. Melander O, Newton-Cheh C, Almegren P, Hedblad B, Berglund G, Engstrom G, et al. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA. 2009 ; 302 (1). 49-57
21. Wilson PW, Pencina M, Jacques P, Selhub J, D'Agostino RS, O'Donnell CJ. C-Reactive Protein and reclassification of cardiovascular risk in the Framingham Heart Study. Circ Cardiovasc Qual Outcomes. 2008 ; 1 (2). 92-97
22. Polonsky T, McClelland RT, Jorgensen NW, Bild DE, Burke GL, Guerci AD, et al. Coronary Artery Calcium Score and risk classification for coronary heart disease prediction. JAMA. 2010 ; 303 (16). 1610-1616
23. Kim PK, Einstein AJ, de Gonzalez AB. Coronary Artery Calcification Screening. Estimated radiation dose and cancer risk. Arch Intern Med. 2009 ; 169 (13). 1188-1194
24. Diamond GA, Kaul S. The things to come of SHAPE: cost and effectiveness of cardiovascular prevention. Am J Cardiol. 2007 ; 99 (7). 1013-1015
25. Ioannidis JPA, Tzoulaki I. What makes a good predictor?: The evidence applied to Coronary Artery Calcium Score. JAMA. 2010 ; 303 (16). 1646-1647
26. Marshall T. Measuring blood pressure: the importance of understanding variation. Rev Bras Hipertens. 2005 ; 12 (2). 75-82
27. Keenan K, Hayen A, Neal B, Irwig L. Long term monitoring in patients receiving treatment to lower blood pressure: analysis of data from placebo controlled randomised controlled trial. BMJ. 2009 ; 338: b1492.
28. Bell KJL, Hayen A, Macaskill P, Craig JC, Neal BC, Fox KM, et al. Monitoring initial response to angiotensin converting enzyme inhibitor based regimens: an individual patient data meta-analysis from randomised placebo controlled trials. Hypertension. 2010 ; 56 (3). 533-539
29. Takahashi O, Glasziou PP, Perera R, Shimbo T, Suwa J, Hiramatsu S, et al. Lipid re-screening: what is the best measure and interval?. Heart. 2010 ; 96: 448-452
30. National Heart Foundation of Australia (National Blood Pressure and Vascular Disease Advisory Committee). Guide to management of hypertension 2008. Updated August 2009. Web version.
31. Chobanian AV, Bakris GR, Black HL, Cushman WC, Green LA, Izzo Jr JL, Jones DW, Materson BJ, Oparil S, Wright Jr JT, Roccella EJ, the National High Blood Pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42(6): 1206-1252.
32. Task Force for the Management of Arterial Hypertension of the ESH and of the ESC. 2007 Guidelines for the Management of Arterial Hypertension. Journal of Hypertension 2007; 25(9): 1105-1187.